DOCSLIB.ORG

The European Cannabis Reporttm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The European Cannabis Reporttm The European Cannabis Report TM July 2018 3rd Edition TM The European Cannabis Report | Table of Contents 2 3rd Edition Table of Contents Introduction 6 Lead Sponsor Foreword 7 Executive Summary 9 An Introduction to Medical Cannabis 10 Market Size 12 Market Overview Methodology Medical Recreational Industrial Legislation 15 Overview Medical Recreational Industrial The Process of Legal Reform Regulation 20 Overview The United Nations Medical Cannabis Programs Cannabis Agencies Healthcare 22 Potential Qualifying Conditions Healthcare Analysis Commercial Opportunities 23 Corporate Social Responsibility 25 Key Countries 28 Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 3 3rd Edition Table of Contents Germany 29 Czech Republic 54 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel Spain 35 France 59 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel The Netherlands 40 Ireland 64 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Israel 45 Portugal 68 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Italy 49 The United Kingdom 72 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 4 3rd Edition Table of Contents Poland 76 Luxembourg 97 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. European Panel 6. European Panel Greece 81 Denmark 101 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. European Panel 5. Consumption Switzerland 85 Sweden 105 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. European Panel 5. Consumption Austria 89 Norway 109 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption Belgium 93 Finland 113 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 5 3rd Edition Table of Contents Estonia 117 Macedonia 134 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption Slovenia 121 Romania 137 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption Croatia 125 Turkey 141 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 6. European Panel Serbia 130 Malta 145 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities Global Industry Insights 148 European Industry Insights 149 Contributors 151 About Prohibition Partners 152 Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Introduction 6 3rd Edition Introduction: The 3rd Edition of the European Cannabis Report™ In just six months, the European cannabis industry has I would like to thank the support of our sponsors, grown more than in the previous five years. Over six new members of our European Country Panel and the countries have announced legalisation, patient numbers dedicated team at Prohibition Partners who are have grown by 40% month on month and over €150m has committed to providing the most comprehensive data been invested in the European industry alone. and insights on the European cannabis industry. The 3rd Edition of The European Cannabis Report™ is I hope you enjoy the report. the most extensive review of the European cannabis industry to date. The report looks at legislation, Stephen Murphy regulation, market size and market opportunities in over Co-Founder & Managing Director 28 European countries, all of which is intricately detailed Prohibition Partners over 150 pages. Lead Sponsor Foreword The European cannabis market presents the world’s the MedReleaf footprint across additional European largest opportunity to expand in the cannabis space. The countries. tides are shifting as countries have increasingly moved toward legalising medical cannabis, bringing greater As the demand for premium medical cannabis products visibility and credibility to this growth industry. And continues to rise, MedReleaf is well positioned to lend although the health and financial benefits of medical our expertise in research and development in this highly cannabis have been well publicised, what has yet to specialised field. Our stringent quality controls are be determined is how control and classification of this aimed at ensuring that pharmaceutical grade standards category will unfold. are not just met, but exceeded. In our constant pursuit of introducing new products to global markets, MedReleaf As Canada’s first and only ISO 9001 and ICH-GMP was the first Canadian licensed producer to offer a certified cannabis producer, MedReleaf is ideally topical cream to be used with CBD cannabis oils, as well suited to expand into this burgeoning market. Outside as other important innovations like colour-coded softgel of Canada, federally legal markets for cannabis are capsules with a focus on patient-safety. Boasting an primarily focused on medical applications, which extensive plant breeding program with geneticists and aligns well with MedReleaf’s core strengths in research master growers providing expertly cultivated cannabis and development, innovation, quality control and varieties in a broad and unique product offering, we pharmaceutical grade standards. A mission to advance have consistently differentiated ourselves as industry the science of cannabis by delivering a consistently leaders and innovators. high product and high-quality experience, serves us well as we expand our global network of partners and MedReleaf is committed to executing on our European regulators. market-entry strategy in a measured and thoughtful manner and look forward to fostering positive With an announced German distribution agreement relationships with partners and regulators across the and a number of other EU distribution agreements European Union as the cannabis industry continues to and activities on the horizon, we look forward to evolve and mature. continuing to establish new partnerships and broaden Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice.
Load more

Recommended publications
  • Appendix 1 (As Supplied by the Authors)
    Appendix 1 (as supplied by the authors): Sources of information regarding how each Canadian province and territory is allowing cannabis retail and online sales, and store locations Jurisdiction Source Store locations Provinces Newfoundland and Labrador Legislation: Bill 20: An Act Clarenville Green Stop (Esso), Clarenville, 258 Memorial Drive, Respecting the Control and Sale A5A1N9 of Cannabis1 C-Shop, Bay Roberts, 230 Conception Bay Highway, A0A1G0 Regulations: Newfoundland and C-Shop, Carbonear, 120 Columbus Drive, A1Y1B3 Labrador Cannabis Regulations2 C-Shop, Conception Bay South, 166 Conception Bay Highway, A1W3A6 List of Retail Stores: Store C-Shop, Corner Brook, 5 Murphy Square, A2H1R4 Locator (Cannabis NL)3 C-Shop, Gander, 100 Laurell Road, A1V2V5 Online Store: Cannabis NL4 C-Shop, Grand Falls-Windsor, 17 Cromer Ave, A2A1X3 C-Shop, Mount Pearl, 150 Old Placentia Road, A1N4Y9 C-shop, St. John's, 260 Blackmarsh Road, A1E1T2 C-shop, St. John's, 55 Stavanger Drive, A1A5E8 C-Shop, Stephenville, 62 Prince Rupert Drive, A2N3W7 Deer Lake Green Stop, Deer Lake, 31 Upper Nicholsville Rd, A8A2G1 High North, Labrador City, 1 Neal Drive, A2V1Y5 Miawpukek Cannabis Boutique, Conne River, 19 Miawpukek Drive, A0H1J0 Paradise Green Stop, Paradise, 1316 Topsail Rd, A1L1N9 The Herbal Centre, St. John's, 394 Kenmount Road, A1B3R2 The Natural Vibe, St. John's, 306 Water Street, A1C1B8 The Reef Cannabis Shop, Holyrood, 386 CBS Highway, A0A2R0 Thomas H. Clarke's Distribution, Portugal Cove - St. Phillips, 1614 Portugal Cove Road, A1M3G3 Tweed, Conception Bay, 81 Conception Bay Highway S Unit 3, A1W3A3 Tweed, Corner Brook, 62 Broadway Avenue, A2H6H4 Tweed, Happy Valley-Goose Bay, 27 Aspen Drive, A0P1C0 Tweed, Mount Pearl, 50 Commonwealth Ave Unit 5, A1N1X1 Tweed, St.
    [Show full text]
  • SUU Alm.Del Bilag 444: Itamar Grotto
    Sundheds- og Ældreudvalget 2017-18 SUU Alm.del Bilag 444 Offentligt MINISTRY OF HEALTH Medical Grade Cannabis - The Israeli Roadmap to Medicalization Prof. Itamar Grotto Associate Director General, Israeli Ministry of Health Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Medical use of Cannabis in ancient times • 5000 years ago in Egyptian tombs • 2700 years ago in India • 2000 years ago in China for the treatment of pain Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH International - Single Convention on Narcotic Drugs 1961 The Cannabis plant is subject to additional measures of control Israel - The Dangerous Drug Ordinance [New Version] - 1973 The Cannabis plant and its products are defined as narcotic substances They are not registered as medicinal products Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Government of Israel Resolutions Government Resolution 3609 (7.8.2011) • Establishes the obligation of the Ministry of Health to serve as “Government Agency” for Cannabis • The multi-ministerial Stirring Committee • The Israeli Medical Cannabis Agency (IMCA) is established Government Resolution 1050 (15.12.2013) • Improving efficiency of prescription, indication inspection, appointing of Physicians and accessibility to service. • Search for feasibility of export • Regulating research. Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Government Resolution 1587 (26.6.2016) - Cannabis for medical purpose and research The “Medicalization” of Cannabis Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Vision of The Israeli Medical Cannabis Agency (IMCA) To support the use of Cannabis for medical purposes exclusively, while preventing misuse and keeping public safety.
    [Show full text]
  • Accepted Manuscript
    Accepted Manuscript Title: Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries Author: Pekka Hakkarainen Vibeke Asmussen Frank Monica J. Barratt Helle Vibeke Dahl Tom Decorte Karoliina Karjalainen Simon Lenton Gary Potter Bernd Werse PII: S0955-3959(14)00173-X DOI: http://dx.doi.org/doi:10.1016/j.drugpo.2014.07.005 Reference: DRUPOL 1418 To appear in: International Journal of Drug Policy Received date: 18-4-2014 Revised date: 4-7-2014 Accepted date: 7-7-2014 Please cite this article as: Hakkarainen, P., Frank, V. A., Barratt, M. J., Dahl, H. V., Decorte, T., Karjalainen, K., Lenton, S., Potter, G., and Werse, B.,Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries, International Journal of Drug Policy (2014), http://dx.doi.org/10.1016/j.drugpo.2014.07.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries Pekka Hakkarainen1, Vibeke Asmussen Frank2, Monica J. Barratt3,6, Helle Vibeke Dahl2, Tom Decorte4, Karoliina Karjalainen5, Simon Lenton6, Gary Potter7 & Bernd Werse8 1 Corresponding author, Department of Alcohol, Drugs and Addiction, National Institute for Health and Welfare (THL), P.O.
    [Show full text]
  • Country Profile Highlights Strategy
    Country Profile Highlights Strategy Legal Framework inside Actors Infrastructure Services for Citizens Services for Businesses What’s eGovernment in Portugal ISA² Visit the e-Government factsheets online on Joinup.eu Joinup is a collaborative platform set up by the European Commission as part of the ISA² programme. ISA² supports the modernisation of the Public Administrations in Europe. Joinup is freely accessible. It provides an observatory on interoperability and e-Government and associated domains like semantic, open source and much more. Moreover, the platform facilitates discussions between public administrations and experts. It also works as a catalogue, where users can easily find and download already developed solutions. The main services are: Have all information you need at your finger tips; Share information and learn; Find, choose and re-use; Enter in discussion. This document is meant to present an overview of the eGoverment status in this country and not to be exhaustive in its references and analysis. Even though every possible care has been taken by the authors to refer to and use valid data from authentic sources, the European Commission does not guarantee the accuracy of the included information, nor does it accept any responsibility for any use thereof. Cover picture © AdobeStock Content © European Commission © European Union, 2018 Reuse is authorised, provided the source is acknowledged. eGovernment in Portugal May 2018 Country Profile .........................................................................................................
    [Show full text]
  • Israeli Cannabis Company 'Together' Announced an Agreement with a Canadian Company to Sell 50 Tons of Cannabis Inflorescences Or 5 Tons of Cannabis Oil
    Israeli cannabis company 'Together' announced an agreement with a Canadian company to sell 50 tons of cannabis inflorescences or 5 tons of cannabis oil The company estimates the potential annual revenue from the deal at hundreds of millions of shekels. "This agreement joins other existing sales agreements in Canada and German totaling 30 tons. These agreements ensure the creation of revenue and cash flow that are not dependent on export approval from the State of Israel, and which will derive from the sale of medical cannabis and its products from areas that we will set up in countries outside of Israel that have the relevant export agreements", said Globus Pharma founding partner Nissim Bracha Israel, Ashkelon, April 11 2018 – 'Together' (TASE: TGTR) announced that its activity company 'Globus Pharma', which specializes in the medical cannabis sector and operates as a subsidiary of 'Together', has signed a Memorandum of Understanding (MoU) to sell medical cannabis or oil to a Canadian company with a license to grow, produce and import medical cannabis to Canada. Under the terms of the agreement, the Canadian company will buy from Globus 50 tons of dried inflorescences of cannabis each year or five tons of medical cannabis oil (the equivalent amount to 50 tons of inflorescences) as part of the terms of the law in Canada and in Israel. In addition, the two companies will collaborate in the field of R&D and promoting technologies in the medical cannabis sector. As of the date of signing the agreement, the parties estimate that sales revenue will amount to between US$3.17 and US$4.7 per gram of inflorescence.
    [Show full text]
  • Rockledge City Council Regular Meeting Notice and Agenda
    ROCKLEDGE CITY COUNCIL REGULAR MEETING NOTICE AND AGENDA Wednesday, February 1, 2017 - 6:00 p.m. Chairman Thomas J. Price Presiding Council Chamber, Rockledge City Hall, 1600 Huntington Lane, Rockledge, FL 32955 *~*~*~*~*~*~* EVERY PERSON ADDRESSING THE CITY COUNCIL MUST COMPLETE A SPEAKER'S CARD The cards are located near the door of the Council Chamber. Completed cards are to be given to the City Clerk before the meeting convenes or prior to the introduction of a particular agenda item. *~*~*~*~*~*~* 1. CALL TO ORDER / ROLL CALL 2. INVOCATION l Councilman Hartselle 3. SALUTE TO THE FLAG 4. APPROVAL OF MINUTES l Regular Meeting on January 18, 2017 Documents: COUNCIL MINUTES 2017 01-18.PDF 5. PRESENTATIONS A. Mayor Price 1. Certificate Of Completion To Councilman Daski: 2016 Florida League Of Cities Advanced Institute For Elected Municipal Officials B. Public Works Director Poole 1. Video: Know Your Waterways 6. FINANCIAL / BUDGET REPORT l None 7. PUBLIC HEARINGS / ORDINANCES / RESOLUTIONS A. Resolution: Providing for the Apportionment of $4.00 of the $14.00 Base Sewer Service Charge Documents: 2017- RESOLUTION SEWER CHARGE APPORTIONMENT.PDF B. Public Hearing: VE-17-01, Vacate Public Utility Easement, Lots 25, 26, 27 and 28, Angela Avenue, Casa Loma Subdivision Documents: PUBLIC HEARING NOTICE VACATE EASEMENT PORTION OF ANGELA AVE CASA LOMA SUBDIVSION.PDF C. Resolution: Vacating Public Utility Easement, Lots 25, 26, 27 and 28, Angela Avenue, Casa Loma Subdivision Documents: 2017- RESOLUTION VACATING EASEMENT, CASA LOMA SUBDIVISION BLOCK A (VE-17-01, RJM MERCO).PDF D. Ordinance: First Reading, Relating to Cannabis Dispensing Facilities and Imposing a Temporary Moratorium on the Opening of Any New Cannabis Dispensing Facility Documents: ORDINANCE NO.
    [Show full text]
  • Brochura HCP V10.3
    PORTUGAL A PRIVILEGED DESTINATION FOR MEDICAL TOURISM Contents - Manuel Caldeira Cabral – Minister of Economy - Adalberto Campos Fernandes – Minister of Health - Salvador de Mello - President of Health Cluster Portugal - Portugal - A Privileged Destination - Healthcare in Portugal - Areas of excellence in Portuguese Healthcare - Cardiology & Cardiac Surgery - Orthopedics - Rehabilitation - Oncology - Plastic Surgery - Obesity - Ophthalmology - OB/GYN - Assisted Reproductive Technology - Check-ups - Portugal facts and figures - How to get in touch or find out more MEDICAL TOURISM IN PORTUGAL Terminal de Cruzeiros do Porto de Leixões Manuel Caldeira Cabral Minister of Economy In the past few years, Portugal has established itself as one of the best touristic destinations all across the world. The growth of this sector in our country has been a major Key for the wealth creation in Portugal, and one of the main drivers for our economy. Last year, 2017, we broke new records again – revenue increased 20%, something we had not seen in the last two decades. So strong is the performance of tourism in Portugal that it accounts for more than half the services exports and 18% of the exports of goods and services. Last year, overall, Portuguese exports Kept growing and represented 42,5% of our GDP, a new record, which clearly shows how sustainable and resilient the Portuguese economy is. We are also aware that the demand for high quality health treatments is growing, namely because of demographics, and we have identified that as a priority in our National Strategy for Tourism 2027. We have some of the best qualified doctors and nurses and modern and functional medical infrastructures that are able to serve both locals and tourists.
    [Show full text]
  • The Canadian Cannabis Story
    A Generational Investment Opportunity THE CANADIAN CANNABIS STORY JOIN THE CONVERSATION / Echelon Wealth Partners echelonpartners.com TABLE OF CONTENTS 3 The Canadian Cannabis Story: A Generational Investment Opportunity 4 Cannabis: A Brief History 5 The Many Forms of Cannabis 5 An Increase in Legal Cannabis-based Products 5 Medical Use 8 Cannabis as an Opiod Alternative 11 Cannabis and Canada: A Strong Growth Story 14 A Global Cannabis Boom: The Next Stage 17 Canadian Cannabis Stocks - An Investment Opportunity to Consider 19 Endnotes echelonpartners.com 2 The Canadian Cannabis Story: A Generational Investment Opportunity THE CANADIAN CANNABIS STORY: A GENERATIONAL INVESTMENT OPPORTUNITY By Echelon Wealth Partners The Canadian Cannabis Story aims to provide readers with a comprehensive look at the cannabis market in Canada through its history, growth, and various production sectors to illuminate the investment opportunity this sector will afford in a rapidly growing global market. The increasing trend in cannabis decriminalization and legalization, both in North America and around the world, has awakened the interest of the investment community. The unique and potential medicinal properties of cannabis and its versatility for other commercial uses are considered the harbingers of an investment with significant growth potential. Canada legalized marijuana for recreational use on October 17, 2018 echelonpartners.com 3 The Canadian Cannabis Story: A Generational Investment Opportunity CANNABIS A Brief History Marijuana is produced from the flower and leaves of cannabis plants, which grow naturally in humid temperate conditions on all continents.1 The two most important varieties of the cannabis plant are sativa and indica, with hemp being a specific species of the sativa plant.
    [Show full text]
  • This Is the Peer Reviewed Version of the Following Article
    This is the peer reviewed version of the following article: Potter, G. R., Barratt, M. J., Malm, A., Bouchard, M., Blok, T., Christensen, A.-S., Decorte, T., Frank, V. A., Hakkarainen, P., Klein, A., Lenton, S., Perälä, J., Werse, B., & Wouters, M. (2015). Global patterns of domestic cannabis cultivation: Sample characteristics and patterns of growing across eleven countries. International Journal of Drug Policy, 26(3), 226–237. which has been published in final form at https://doi.org/10.1016/j.drugpo.2014.12.007 This article may be used for non-commercial purposes in accordance with Elsevier’s Article Sharing policy and Hosting policy © 2014. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Accepted Manuscript Title: Global patterns of domestic cannabis cultivation: Sample characteristics and patterns of growing across eleven countries Author: Gary R. Potter Monica J. Barratt Aili Malm Martin Bouchard Thomas Blok Anne-Sofie Christensen Tom Decorte Vibeke Asmussen Frank Pekka Hakkarainen Axel Klein Simon Lenton Jussi Peral¨ a¨ Bernd Werse Marije Wouters PII: S0955-3959(14)00363-6 DOI: http://dx.doi.org/doi:10.1016/j.drugpo.2014.12.007 Reference: DRUPOL 1503 To appear in: International Journal of Drug Policy Received date: 22-7-2014 Revised date: 6-12-2014 Accepted date: 8-12-2014 Please cite this article as: Potter, G. R., Barratt, M. J., Malm, A., Bouchard, M., Blok, T., Christensen, A.-S., Decorte, T., Frank, V. A., Hakkarainen, P., Klein, A., Lenton, S., Peral¨ a,¨ J., Werse, B., and Wouters, M.,Global patterns of domestic cannabis cultivation: sample characteristics and patterns of growing across eleven countries, International Journal of Drug Policy (2014), http://dx.doi.org/10.1016/j.drugpo.2014.12.007 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • ©Copyright 2008 Sunil Kumar Aggarwal
    ©Copyright 2008 Sunil Kumar Aggarwal The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress Sunil Kumar Aggarwal A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2008 Program Authorized to Offer Degree: Geography University of Washington Graduate School This is to certify that I have examined this copy of a doctoral dissertation by Sunil Kumar Aggarwal and have found that it is complete and satisfactory in all respects, and that any and all revisions required by the final examining committee have been made. Chair of the Supervisory Committee: ___________________________________________________ Jonathan Mayer Reading Committee: __________________________________________________ Jonathan Mayer _________________________________________________ Richard Morrill ___________________________________________________ Craig ZumBrunnen ___________________________________________________ Gregory Carter ___________________________________________________ Ethan Russo Date:__________________________ In presenting this dissertation in partial fulfillment of the requirements for the doctoral degree at the University of Washington, I agree that the Library shall make its copies freely available for inspection. I further agree that extensive copying of the dissertation is allowable only for scholarly purposes, consistent with “fair use” as prescribed in the U.S. Copyright Law. Requests for copying or reproduction of this dissertation
    [Show full text]
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Medicinal Use of Cannabis 3Rd Edition
    M E M O R A N D U M Medicinal use of Cannabis 3rd edition 2015 04/12/2015 Medicines Control & Inspection File no.2013113424/ Axel Heides Gade 1 DK-2300 Copenhagen S Frank Bøgh Madsen [email protected] Email: [email protected] Page 2 04/12/2015 Danish Medicines Agency Contents 1. Introduction ................................................................................................ 3 2. The body's own cannabinoids and receptors .............................................. 3 3. Knowledge about intoxicating and harmful effects and the prevalence of Cannabis......................................................................................................... 4 3.1. The Dutch Ministry of Health's brochure about side effects of medicinal use of Cannabis .......................................................................................... 5 4. Rules about Cannabis as a euphoriant substance ....................................... 6 4.1. List A – Cannabis ............................................................................... 6 4.2. List B – THC in pure form and other cannabinoids ............................ 7 4.3. CBD – in pure form or in hemp products ............................................ 8 5. Positive effects of medicines containing active substances from Cannabis and clinical trials ............................................................................................ 8 5.1. Other scientific evidence about Cannabis and cannabinoids ............ 10 6. Rules about medicines requiring a marketing authorisation (Sativex®)
    [Show full text]